Integral Derivatives’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Integral Derivatives’s Portfolio ANTH Stock Details ANTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-28,047	Closed	-$48.3K	–	1366
2017 Q3	$40K	Buy	28,047 +4,100	+17%	+$5.82K	﹤0.01%	1100
2017 Q2	$39K	Sell	23,947 -1	-0%	-$2	﹤0.01%	1065
2017 Q1	$82K	Buy	23,948 +2,863	+14%	+$13.5K	﹤0.01%	1090
2016 Q4	$109K	Buy	+21,085	New	+$365K	﹤0.01%	1058

Other funds holding ANTH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Integral Derivatives's ANTH Position: Q4 2017 in Review

Integral Derivatives sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q4 2017, closing a stake of 28,047 shares — an estimated $48.3K sold.

Integral Derivatives first reported a position in ANTH in Q4 2016 and held it in 4 quarters. The position peaked at $109K in Q4 2016. 37 funds tracked by Wall St. Rank hold ANTH as of Q4 2017.

Integral Derivatives reported no remaining Anthera Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
Integral Derivatives sold 28,047 Anthera Pharmaceuticals, Inc. shares in Q4 2017, an estimated $48.3K.
Integral Derivatives first reported a position in Anthera Pharmaceuticals, Inc. in Q4 2016 and held it in 4 quarters.
Integral Derivatives's Anthera Pharmaceuticals, Inc. position peaked at $109K in Q4 2016.
37 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q4 2017.

Based on Integral Derivatives's 13F filing for Q4 2017, filed 14 Feb 2018.